La vendita allo scoperto per Aethlon Medical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Aethlon Medical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Aethlon Medical (NASDAQ:AEMD) Azioni, Report sulle vendite allo scoperto

Aethlon Medical

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Aethlon Medical Inc

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

Biotech

News

General

AEMD

APDN

CMRX

GOVX

TNXP

VRAX

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

Shares of Tesla, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply in today's pre-market trading after a report on Sunday, suggested that the upcoming regulatory framework might ease <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms">mandates for self-driving vehicles</a>.
The transition team of President-elect Donald Trump has told advisors that it aims to make a framework for fully self-driving vehicles a priority for the Transportation Department, reported Bloomberg, citing people familiar with the matter.
Tesla shares jumped 8.2% to $347.13 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Apollomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) gained 80.3% to $0.1725 in pre-market trading after declining 8% on Friday.</li>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) rose 63% to $0.4238 in pre-market trading after dipping around 12% on Friday.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) gained 51.1% to $0.2720 in pre-market trading.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) gained 29.1% to $0.2655 in pre-market trading.</li>
<li>Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) gained 28% to $21.63 in pre-market trading.</li>
<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) gained 15.1% to $0.9450 in pre-market trading after dipping 39% on Friday.</li>
<li>Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) climbed 12.7% to $15.75 in pre-market trading after the company said initial Phase 1 data suggesting Nexiguran Ziclumeran, an in vivo CRISPR/Cas9 gene editing therapy, may benefit ATTR Amyloidosis Progression.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) gained 12.7% to $0.45 in pre-market trading.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 11.1% to $20.64 in pre-market trading after gaining more than 3% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares tumbled 33.2% to $0.4600 in pre-market trading after gaining around 13% on Friday.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 28.5% to $1.20 in pre-market trading. CareMax reached agreements to sell Management Services Organization and Core Centers&#8217; assets.</li>
<li>Paramount Gold Nevada Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZG#NYSE">PZG</a>) shares fell 27.8% to $0.3301 in pre-market trading after gaining around 4% on Friday.</li>
<li>QMMM Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) declined 23.4% to $5.61 in pre-market trading after falling 13% on Friday.</li>
<li>The Arena Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) dipped 23.4% to $1.34 in pre-market trading. Arena Group shares jumped 207% on Friday after it announced its first ever profitable quarter.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) shares dipped 22.1% to $0.9895 in pre-market trading. Siyata Mobile recently reported better-than-expected third-quarter EPS results.</li>
<li>Eterna Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) fell 15% to $0.7100 in pre-market trading after dipping 12% on Friday.</li>
<li>Cyclerion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) fell 14% to $2.22 in pre-market trading after jumping more than 45% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) fell 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLM

AREN

ATCH

CMAX

CYCN

ERNA

FLYE

LAZR

LBRT

MNDR

NTLA

QMMM

SMCI

SYTA

TSLA

VVPR

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 83.61 percent increase over losses of $(1.22) per share from the same period last year.

Earnings

Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline

ACXP

ADAP

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) will release its quarterly earnings report on Wednesday, 2024-11-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Aethlon Medical to report an earnings per share (EPS) of $-0.19.
Anticipation surrounds Aethlon Medical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.03, leading to a 16.86% drop in the share price the following trading session.
Here's a look at Aethlon Medical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-1.23</td>
<td>-1.23</td>
<td>-1.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.34</td>
<td>-0.91</td>
<td>-1.37</td>
<td>-1.22</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731438218_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/AEMD/earnings">To track all earnings releases for Aethlon Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Aethlon Medical's Earnings

WIIM

Aethlon Medical shares are trading higher after the company announced it enrolled its first patient in its Australian hemopurifier cancer trial targeting patients with solid tumors unresponsive to anti-pd-1 therapy.

Aethlon Medical Enrolls First Patient In Australian Hemopurifier Cancer Trial; Study Targets Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

MRNA

'UK detects two more cases of new mpox variant' - Reuters

BWVI

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares increased by 51.2% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock rose 23.64% to $1.83. The company's market cap stands at $136.7 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 21.54% to $0.9. The company's market cap stands at $65.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 18.47% to $1.09. The market value of their outstanding shares is at $1.7 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock increased by 10.83% to $0.44. The market value of their outstanding shares is at $6.1 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock rose 10.28% to $0.35. The market value of their outstanding shares is at $26.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 11.8% to $0.6 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 11.53% to $0.23. The market value of their outstanding shares is at $1.4 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $2.7 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares declined by 9.44% to $1.11. The company's market cap stands at $67.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 9.31% to $0.58. The market value of their outstanding shares is at $5.8 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock decreased by 7.2% to $2.41. The company's market cap stands at $5.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

CLSD

CTCX

NIVF

TIVC

WINT

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

Aethlon Medical shares are trading higher after the company announced that it received granted ethics committee approval for Hemopurifier cancer treatment. Also, the European Commission recommended extending the indication of the smallpox and mpox vaccine to adolescents.

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Global

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

Aethlon Receives Ethics Committee Approval For Hemopurifier Cancer Trial In India, Targeting Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy

US To Stay Committed In Bringing Mpox Outbreak Under Control

Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier&#xAE; in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies
SAN DIEGO, Sept. 16, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4253946-1&amp;h=3330854438&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fwww.aethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOjhhMGQxZTQ5ODhlNGJjNDNiOTFiOWI3OGQyNTg0NTkyOjY6YjRmZDo1ZDY5N2I5YTA1MGRiODQyMmUyM2NlODE0ODI1OGExZWQzZGVlYzFiODQ3YjNjMmU4YmZjMzY0ZjE1OGJiZmU0OnA6Rg&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, 2024 to begin screening and enrolling patients in its safety, feasibility and dose-finding clinical trial of the Hemopurifier&#xAE; in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda&#xAE; (pembrolizumab) or Opdivo&#xAE; (nivolumab) (AEMD-2022-06 Hemopurifier Study). The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia.
The activation follows the previously announced approval by the Human Research Ethics Committee at Central Adelaide Local Health Network on June 13, 2024, and the Research Governance office at Royal Adelaide Hospital, on September, 3 2024, as well as the notification of the Therapeutic Good Administration (TGA) and completion of a Site Initiation Visit on September 9, 2024.

Aethlon Medical Announces Activation Of Royal Adelaide Hospital To Begin Patient Screening And Enrollment In Hemopurifier Cancer Trial

Aethlon Medical ( ($AEMD) ) just unveiled an update. Aethlon Medical, Inc. has elevated James B. Frakes from Interim to permanent Chief Executive O...

Aethlon Medical Appoints James B. Frakes as CEO

Aethlon Medical (AEMD) announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemop...

Aethlon Medical enrolls first patient in Hemopurifier cancer trial in Australia

Here are the major earnings after the close today

Aethlon Medical GAAP EPS of -$0.20 in-line

As of September 30, 2024, Aethlon Medical (AEMD) had a cash balance of approximately $6.9M. "During Q2 and subsequent period, we continued advancin...

Aethlon Medical reports Q3 EPS (20c) vs. ($1.22) last year

Aethlon Medical ( ($AEMD) ) just unveiled an update. Aethlon Medical, Inc. has reported significant advancements in its oncology trials, enrolling ...

Aethlon Medical Advances Oncology Trials and Global Expansion

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript

Aethlon ( ($AEMD) ) has released its Q2 earnings. Here is a breakdown of the information Aethlon presented to its investors. Aethlon Medical, Inc.,...

Aethlon Medical Reports Progress in Oncology Trials

Aethlon (AEMD) has disclosed a new risk, in the Accounting & Financial Operations category. Aethlon faces significant financial and operational ris...

Aethlon's Future at Risk: Financial Struggles, Stockholder Dilution, and Market Challenges Loom

Maxim Group analyst Anthony Vendetti maintained a Hold rating on Aethlon Medical (AEMD – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Their Hold Rating for Aethlon Medical (AEMD)

AOIFF

BDORY

NLCP

PVCT

SMSI

SONO

SPRU

TLPH

TTEK

VXRT

Small Cap

Press Releases

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Comments

Aethlon Medical

Vendite allo scoperto

Aethlon Medical (NASDAQ:AEMD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO